HPV CD40HVac is under clinical development by LinKinVax Europe Spas and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer. According to GlobalData, Phase II drugs for Human Papillomavirus (HPV) Associated Cancer have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HPV CD40HVac’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HPV CD40HVac overview

Vaccine is under development for the treatment of human papillomavirus (HPV) associated oropharyngeal cancer and head and neck cancer. It acts by targeting CD40 ligand and is being developed based on dendritic cell-targeting vaccine platform.

LinKinVax Europe Spas overview

LinKinVax Europe Spas is a biotechnology firm in the clinical stage. By utilising research undertaken at the Vaccination Research Institute, it is building a new protein-based vaccine platform that can speed up vaccine availability (VRI). The company is headquartered in France.

For a complete picture of HPV CD40HVac’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.